Department of Tumor Biology
Seeking to understand the processes involved in metastasis for the development of preventive and treatment strategies.
Laboratory studies are ongoing to characterize the role of a protein called Kindlin-1 on breast cancer metastasis and identify potential druggable targets to block this effect.
These studies may inform preventive approaches that could reduce breast cancer deaths.
Dr. Lidereau's BCRF project focuses on understanding the processes involved in metastasis, particularly how tumor cells can migrate, or move from one place to another, a characteristic that normal breast cells do not have.
Her lab uses state-of-the-art cell technologies to study the role of proteins that control tissue architecture and how they become dysregulated during tumor progression, thus allowing tumor cell migration. They have identified an essential protein called Kindlin-1 that is over-expressed in cancer cells.
Kindlin-1 is a structural protein that interacts with signling proteins in the cell architecture called integrins. Dr. Lidereau's team has shown that Kindlin-1 causes tumor cells to become mobile and increases their ability to invade (break through) neighboring tissue.
In the coming year, Dr. Lidereau's team will further investigate the molecular pathways involved in Kindlin-1 / integrin interactions and their relationship with altered migration and invasion of cancer cells. Her team has characterized two proteins that block this interaction. The specific effect of these proteins will be evaluated on cancer cell survival, invasive capacities, and metastatic potential.
The studies may lead to new therapeutic strategies for aggressive breast cancers.
Dr. Rosette Lidereau received her PhD in oncology and immunology in 1987 from the Pasteur Institute (working with Chairman and Prof. Barret-Sinoussi) and completed a fellowship in the Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda (Prof. R. Callahan). In 1992, she was recruited by the INSERM (Institut National des Sciences et de la Recherche Médicale), where she served as a Research Director. From 2000, she headed the INSERM Unit U735, a laboratory dedicated to the molecular characterization of breast cancers at the Centre René Huguenin, Saint-Cloud, France.
Dr. Lidereau's scientific career has focused on the biology of breast cancer. Her research interests are the evaluation of oncogenes and the implication of tumor suppressor genes in breast tumorigenesis and their impact in the clinic as prognostic and predictive factors in breast cancer. Her work has been published in peer reviewed journals in which she has authored over 250 scientific articles. She has received several awards including the Henry et Mary-Jane Mitjavile prize from the Academy of Medicine (2005). In addition, she has been actively involved in numerous national and international organizations, including the international TRANSBIG research network and European Union Programmes (framework IV and VI).
Currently she pursues her research activities in the Genetics Laboratory in the Department of Tumor Biology at Institut Curie, Paris. Her investigations focus on the molecular determinants of breast cancer metastasis and their involvement in organ-specificity.